Mercer Global Advisors Inc. ADV Acquires New Position in Insmed Incorporated (NASDAQ:INSM)

Mercer Global Advisors Inc. ADV acquired a new stake in Insmed Incorporated (NASDAQ:INSM) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,281 shares of the biopharmaceutical company’s stock, valued at approximately $227,000.

Other hedge funds have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in Insmed in the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC boosted its position in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in shares of Insmed during the fourth quarter worth $86,000.

Insider Activity at Insmed

In other news, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the transaction, the chief executive officer now owns 334,186 shares in the company, valued at approximately $27,079,091.58. This represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. This represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 150,559 shares of company stock worth $11,056,634 over the last quarter. Company insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Insmed in a research note on Wednesday, March 19th. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Guggenheim reaffirmed a “buy” rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Finally, Truist Financial boosted their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $94.63.

Insmed Price Performance

INSM stock opened at $68.12 on Friday. The firm has a market cap of $12.41 billion, a price-to-earnings ratio of -12.19 and a beta of 0.84. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company’s fifty day simple moving average is $71.57 and its 200 day simple moving average is $73.10.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.06) EPS. On average, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.